The Aryl Hydrocarbon Receptor pipeline drugs market research report outlays comprehensive information on the Aryl Hydrocarbon Receptor targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Aryl Hydrocarbon Receptor pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Gastrointestinal, Oncology, Immunology, and Metabolic Disorders which include the indications Ulcerative Colitis, Inflammatory Bowel Disease, Solid Tumor, Breast Cancer, Inflammation, Graft Versus Host Disease (GVHD), and Type 1 Diabetes (Juvenile Diabetes). It also reviews key players involved in Aryl Hydrocarbon Receptor targeted therapeutics development with respective active and dormant or discontinued products.
The Aryl Hydrocarbon Receptor pipeline targets constitutes close to 23 molecules. Out of which, approximately 20 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Phase III, Phase I, IND/ CTA Filed, Preclinical, and Discovery stages are 1, 2, 4, 2, 8, and 3 respectively. Similarly, the universities portfolio in Preclinical, and Discovery comprises 2, and 1 molecule.
Aryl Hydrocarbon Receptor overview
Aryl hydrocarbon receptor is a protein encoded by the AHR gene. It mediates biochemical and toxic effects of halogenated aromatic hydrocarbons. It involved in cell-cycle regulation. It plays an important role in the development and maturation of many tissues. It regulates the circadian clock by inhibiting the basal and circadian expression of the core circadian component PER1.
For a complete picture of Aryl Hydrocarbon Receptor’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
